JP2013129675A5 - - Google Patents

Download PDF

Info

Publication number
JP2013129675A5
JP2013129675A5 JP2013068780A JP2013068780A JP2013129675A5 JP 2013129675 A5 JP2013129675 A5 JP 2013129675A5 JP 2013068780 A JP2013068780 A JP 2013068780A JP 2013068780 A JP2013068780 A JP 2013068780A JP 2013129675 A5 JP2013129675 A5 JP 2013129675A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
construction
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013068780A
Other languages
English (en)
Japanese (ja)
Other versions
JP5568154B2 (ja
JP2013129675A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013129675A publication Critical patent/JP2013129675A/ja
Publication of JP2013129675A5 publication Critical patent/JP2013129675A5/ja
Application granted granted Critical
Publication of JP5568154B2 publication Critical patent/JP5568154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013068780A 2007-10-22 2013-03-28 Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 Expired - Fee Related JP5568154B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98167707P 2007-10-22 2007-10-22
US60/981,677 2007-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010530173A Division JP2011500727A (ja) 2007-10-22 2008-10-20 Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Publications (3)

Publication Number Publication Date
JP2013129675A JP2013129675A (ja) 2013-07-04
JP2013129675A5 true JP2013129675A5 (enExample) 2014-01-16
JP5568154B2 JP5568154B2 (ja) 2014-08-06

Family

ID=40352187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530173A Pending JP2011500727A (ja) 2007-10-22 2008-10-20 Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
JP2013068780A Expired - Fee Related JP5568154B2 (ja) 2007-10-22 2013-03-28 Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010530173A Pending JP2011500727A (ja) 2007-10-22 2008-10-20 Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用

Country Status (15)

Country Link
US (1) US8907095B2 (enExample)
EP (1) EP2217596B8 (enExample)
JP (2) JP2011500727A (enExample)
KR (1) KR20100075643A (enExample)
CN (1) CN101910151A (enExample)
AR (1) AR068950A1 (enExample)
AU (1) AU2008317057B8 (enExample)
CA (1) CA2703203C (enExample)
CL (1) CL2008003116A1 (enExample)
IL (1) IL205251A0 (enExample)
MX (1) MX2010004450A (enExample)
PE (1) PE20091343A1 (enExample)
TW (1) TW200922578A (enExample)
WO (1) WO2009055331A2 (enExample)
ZA (1) ZA201002959B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318404B1 (en) 2008-07-16 2013-08-21 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
EP2324036B1 (en) 2008-07-16 2014-12-03 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8410122B2 (en) * 2008-12-23 2013-04-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
EP2408780A2 (en) * 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
AR076024A1 (es) * 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CA2764387A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
EP2462123B1 (en) * 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US9409918B2 (en) 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
TWI471095B (zh) 2009-12-21 2015-02-01 Nippon Soda Co 環胺化合物及殺蟎劑
JP2013047188A (ja) * 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119作動薬
AR081721A1 (es) * 2010-02-25 2012-10-17 Nippon Soda Co Compuesto de amina ciclica y acaricida
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011159657A1 (en) * 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
KR101705390B1 (ko) 2012-06-25 2017-02-09 강원대학교산학협력단 이중환 구조를 갖는 신규한 gpcr 효능제
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
UY35750A (es) 2013-09-26 2015-04-30 Mnemosyne Pharmaceuticals Inc Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
EA037299B1 (ru) 2014-09-17 2021-03-05 Селджен Кар Ллс Ингибиторы mk2 и их применения
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
CN111630051B (zh) 2017-11-01 2023-12-26 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃螺环化合物
KR102731925B1 (ko) 2017-11-01 2024-11-18 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 멀티시클릭 화합물
KR102731924B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
KR102732404B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 화합물
US10865194B2 (en) * 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
EP3924333A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
JP7449300B2 (ja) 2019-02-15 2024-03-13 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
EP3924337A1 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted bicyclic compounds as farnesoid x receptor modulators
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
RS65019B1 (sr) 2019-05-10 2024-01-31 Deciphera Pharmaceuticals Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
CN119241444A (zh) 2019-06-17 2025-01-03 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
CN116082188A (zh) * 2023-02-14 2023-05-09 都创(上海)医药开发有限公司 一种以3-氟-4-氨基苯腈为原料合成4-溴-3-氯-5-氟苯腈的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
CA1256116A (en) 1984-09-20 1989-06-20 Joseph E. Moore Fungicidal n-cyanoalkyl-n-haloalkylthio sulfonamides
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
EP0900204A4 (en) 1996-04-23 2001-03-21 Lilly Co Eli HETEROCYCLIC CONNECTIONS
TR199901570T2 (xx) 1996-10-30 1999-09-21 Schering Corporation N�rokinin antagonistleri olarak piperazin t�revleri
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
CA2292388C (en) 1997-05-14 2004-07-20 Atherogenics, Inc. Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
ATE240120T1 (de) 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
DE60125227T2 (de) 2000-12-01 2007-09-20 Astellas Pharma Inc. Verfahren zum screening von diabetes-heilverfahren
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
CA2515963A1 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0413384A (pt) 2003-08-07 2006-10-17 Schering Corp inibidores da proteìna farnesil transferase como agentes antitumores
HRP20090093T3 (en) 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20090105221A1 (en) 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4975739B2 (ja) 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
EP1931654B1 (en) 2005-09-16 2009-04-22 Arena Pharmaceuticals, Inc. Modulators of metabolism and the treatment of disorders related thereto
TW200806662A (en) 2005-12-01 2008-02-01 Organon Nv 8-azabicyclo[3.2.1]octane derivatives
PL1976828T3 (pl) * 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4

Similar Documents

Publication Publication Date Title
JP2013129675A5 (enExample)
JP2013501720A5 (enExample)
JP2013512915A5 (enExample)
JP2013542218A5 (enExample)
JP2015530408A5 (enExample)
JP2015512931A5 (enExample)
JP2013537203A5 (enExample)
JP2016505614A5 (enExample)
JP2015537008A5 (enExample)
JP2013047244A5 (enExample)
JP2014526533A5 (enExample)
JP2017222697A5 (enExample)
JP2016537368A5 (enExample)
JP2013540755A5 (enExample)
JP2014063155A5 (enExample)
JP2014508811A5 (enExample)
JP2016509137A5 (enExample)
JP2011137045A5 (enExample)
JP2015199738A5 (enExample)
JP2015501841A5 (enExample)
JP2009001551A5 (enExample)
JP2014028916A5 (enExample)
JP2014063154A5 (enExample)
JP2012526168A5 (enExample)
JP2016503403A5 (enExample)